In this phase II trial, we evaluated the clinical outcomes and safety profile of a modified triplet chemotherapy regimen with FOLFOX-A in patients with metastatic or advanced unresectable HER2 negative gastric/GEJ adenocarcinoma. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.